Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.56 |
| ▸ | ITGAV | P06756 | 3/20 | 0.56 |
| ▸ | MC4R | P32245 | 5/20 | 0.47 |
| ▸ | MC5R | P33032 | 5/20 | 0.47 |
| ▸ | MC3R | P41968 | 5/20 | 0.47 |
| ▸ | MC1R | Q01726 | 5/20 | 0.47 |
| ▸ | CTSG | P08311 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 2/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.45 |
| ▸ | TSLP | Q969D9 | 5/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13870381 | 1.00 | ITGB3 (0.56) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13748443 | 1.00 | ITGB3 (0.56) | ITGB3ITGAVMC4RMC5RMC3R | |
| Maraciclatide SCHEMBL29408682 | 1.00 | ITGB3 (0.55) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL12353644 | 0.97 | ITGB3 (0.51) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL14324942 | 0.96 | ITGB3 (0.53) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL12353684 | 0.96 | ITGB3 (0.50) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13061299 | 0.95 | ITGB3 (0.49) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL12462751 | 0.95 | ITGB3 (0.49) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL20809940 | 0.95 | ITGB3 (0.49) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13887996 | 0.95 | ITGB3 (0.49) | ITGB3ITGAVMC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023166305-A1 | METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS | SERAC HEALTHCARE LTD (GB) | 2023-09-07 | — | — | WO | disclosed |
| US-20130129623-A1 | RADIOPHARMACEUTICAL COMPOSITIONS | GE HEALTHCARE LIMTED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20090203584-A1 | Peptide-based Compounds | GE HEALTHCARE LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-7521419-B2 | Peptide-based compounds | GE HEALTHCARE AS (NO) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203584-A1 | Peptide-based Compounds | ITGB3, ITGAV, SELPLG | ITGB3 1/4885ITGAV 2/4885MC4R 874/4885 |
| US-20130129623-A1 | RADIOPHARMACEUTICAL COMPOSITIONS | TYMP, KIT, CHEK1 | ITGB3 2899/4885ITGAV 3591/4885MC4R 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.